journal article·2024-03

Super‐Stable Homogeneously Sustained‐Release System Mediates Transcatheter Arterial Ionic‐Embolization Strategy for Hepatocellular Carcinoma Therapy

Xuqi Peng, Yating Zheng, Yi Xue, Xiaoliu Liang, Pan He, Hu Chen, Peng He, Yisheng Peng, Zhenwen Zhao, Yulun Chen, Xiran Gui, Lei Yang, Yongfu Xiong, Juan Lin, Yesi Shi, Chengchao Chu, Yang Zhang, Gang Liu

Advanced Functional Materials· Volume 34· Issue 11
Publisher page

Abstract

Abstract The clinical effectiveness of locoregional therapies in treating hepatocellular carcinoma (HCC) is frequently constrained by multi‐drug resistance and/or tumor metastasis. To surmount these challenges, a promising approach, transcatheter arterial ionic‐embolization (TAIE) is proposed, which can specifically and continuously disrupt the intracellular ionic balance to significantly inhibit tumor activity and invasion. The hydrophilic micro‐nanoscale sodium chloride particles (SCPs) are ingeniously intermixed with hydrophobic lipiodol to create a super‐stable homogeneous embolic formulation (lipiodol‐sodium chloride, LSC). After interventional administration, the LSC selectively deposits in HCC lesions, where lipiodol stably delivers SCPs to disrupt the cell's ionic balance, causing cell death without drug resistance. Notably, it is demonstrated that LSC can significantly hinder tumor cell migration and invasion. The mechanism is through SCP disruption of the ionic balance, which induces cell swelling and subsequent vimentin hydrolysis‐mediated cytoskeletal remodeling. In addition, it is found that LSC treatment notably downregulates the expression of MYLK, TLN, and THBS2 genes in the focal adhesion (FA) signaling pathway of HepG2 cells. LSC formulation integrated tumor‐specific deposition, intratumoral sustained release, efficient tumoricidal activity, significant metastasis inhibition, and excellent biological safety, thereby demonstrating superior in vivo tumor therapeutic effects via TAIE strategy, and showing a promising cancer therapeutic approach for clinical application.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Intracranial Aneurysms: Treatment and Complications · Nanoplatforms for cancer theranostics · Vascular Malformations Diagnosis and Treatment

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Vaccines for Infectious Diseases Center for Molecular Imaging and Translational Medicine Xiang An Biomedicine Laboratory National Innovation Platform for Industry‐Education Integration in Vaccine Research School of Public Health Xiamen University Xiamen 361002 China

Department of Burns and Plastic & Wound Repair Surgery Xiang'an Hospital of Xiamen University School of Medicine Xiamen University Xiamen 361102 China

Department of Hepatobiliary Surgery Academician (Expert) Workstation Affiliated Hospital of North Sichuan Medical College Nanchong 637600 China

Research Unit of Cellular Stress of Chinese Academy of Medical Sciences Cancer Research Center of Xiamen University School of Medicine Xiamen University Xiamen 361102 China

Eye Institute of Xiamen University Fujian Provincial Key Laboratory of Ophthalmology and Visual Science School of Medicine Xiamen University Xiamen 361102 China

Shen Zhen Research Institute of Xiamen University Shenzhen 518057 China

Center for Nanomedicine and Department of Anesthesiology Perioperative and Pain Medicine Brigham and Women's Hospital Harvard Medical School Boston MA 02115 USA

Funding

Major State Basic Research Development Program of China · National Natural Science Foundation of China · Fundamental Research Funds for the Central Universities · China Postdoctoral Science Foundation · Shenzhen Science and Technology Innovation Program · Program for New Century Excellent Talents in University · Natural Science Foundation of Fujian Province

References (38)

Show source-provided references
1. 10.1038/s41572-020-00240-310.1038/s41572-020-00240-3 ↗
2. 10.1038/nrclinonc.2014.12210.1038/nrclinonc.2014.122 ↗
3. 10.1016/j.jhep.2017.03.00710.1016/j.jhep.2017.03.007 ↗
4. 10.1016/j.jhep.2015.11.01110.1016/j.jhep.2015.11.011 ↗
5. 10.1002/jcb.2610710.1002/jcb.26107 ↗
6. 10.1002/viw2.1810.1002/viw2.18 ↗
7. 10.1021/cr300360k10.1021/cr300360k ↗
8. 10.1152/physrev.00018.201110.1152/physrev.00018.2011 ↗
9. 10.1002/cphy.c20001810.1002/cphy.c200018 ↗
10. 10.1016/j.canlet.2012.03.03610.1016/j.canlet.2012.03.036 ↗
11. 10.1038/s41467-020-15524-110.1038/s41467-020-15524-1 ↗
12. 10.1038/nchem.202110.1038/nchem.2021 ↗
13. 10.1021/jacs.6b0172310.1021/jacs.6b01723 ↗
14. 10.1039/C7NR02955A10.1039/C7NR02955A ↗
15. 10.1021/acsnano.1c0949610.1021/acsnano.1c09496 ↗
16. 10.1007/s00259-021-05654-z10.1007/s00259-021-05654-z ↗
17. 10.1016/j.cej.2023.14606110.1016/j.cej.2023.146061 ↗
18. 10.7150/thno.6845610.7150/thno.68456 ↗
19. 10.1002/advs.20190086510.1002/advs.201900865 ↗
20. 10.1002/hep.2620210.1002/hep.26202 ↗
21. 10.1038/natrevmats.2016.3410.1038/natrevmats.2016.34 ↗
22. 10.1016/j.chempr.2019.06.00310.1016/j.chempr.2019.06.003 ↗
23. 10.1021/bm300796q10.1021/bm300796q ↗
24. 10.1002/adma.20160311410.1002/adma.201603114 ↗
25. Cameron I. L. · Cancer Res. · 1980 · 40 · 1493
26. 10.1083/jcb.90.3.76910.1083/jcb.90.3.769 ↗
27. 10.1021/jacs.0c0948210.1021/jacs.0c09482 ↗
28. 10.1016/j.chempr.2019.05.02310.1016/j.chempr.2019.05.023 ↗
29. 10.1002/adma.20190405810.1002/adma.201904058 ↗
30. 10.1007/s10254-003-0009-x10.1007/s10254-003-0009-x ↗
31. 10.1111/cas.1407910.1111/cas.14079 ↗
32. 10.1016/j.tcb.2020.06.00410.1016/j.tcb.2020.06.004 ↗
33. 10.1126/science.121575910.1126/science.1215759 ↗
34. 10.1186/1471-2407-12-26310.1186/1471-2407-12-263 ↗
35. 10.3892/ol.2014.251210.3892/ol.2014.2512 ↗
36. Zhu Y. · J buon · 2019 · 24 · 608
37. 10.21037/atm-20-724410.21037/atm-20-7244 ↗
38. 10.1039/C4RA15385E10.1039/C4RA15385E ↗